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Abstract
Despite an increased risk of coronary artery disease (CAD) in persons infected with human 
immunodeficiency virus (HIV), few data are available on primary prevention of CAD in this 
population. In this retrospective cohort study, HIV-infected patients treated in an academic 
medical center HIV Specialty Clinic between 1996 and 2010 were matched by age, gender, and 
ethnicity to a cohort of presumed uninfected persons followed in an academic medical center 
Internal Medicine primary care clinic. We compared CAD primary prevention care practices 
between the two clinics, including use of aspirin, HMG-CoA reductase inhibitors (“statins”), and 
anti-hypertensive drugs. CAD risk between the two groups was assessed with 10-year 
Framingham CAD risk scores. In the comparative analysis, 890 HIV-infected persons were 
compared to 807 controls. Ten-year Framingham CAD Risk Scores were similar in the two groups 
(median, 3; interquartile range [IQR], 0–5). After adjusting for relevant risk factors, HIV-infected 
persons were less likely to be prescribed aspirin (odds ratio [OR] 0.53; 95% confidence interval 
[CI], 0.40–0.71), statins (OR, 0.70; 95% CI, 0.53–0.92), and anti-hypertensive drugs (OR, 0.63; 
95% CI, 0.50–0.79) than persons in the control group. In summary, when compared to 
demographically similar uninfected persons, HIV-infected persons treated in an HIV specialty 
clinic were less likely to be prescribed medications appropriate for CAD risk reduction. Improving 
primary preventative CAD care in HIV specialty clinic populations is an important step toward 
diminishing risk of heart disease in HIV-infected persons.
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Introduction
With the aging of HIV-infected persons in the USA, coronary artery disease (CAD) has 
emerged as a leading cause of morbidity and mortality in this population (ATCC, 2010; 
Marin et al., 2009). Recent evidence suggests that persons living with HIV (PLHIV) are at 
almost 50% higher risk for myocardial infarction than the general population even after 
controlling for traditional CAD risk factors (Freiberg et al., 2013). Research into the 
pathophysiology of atherosclerosis in PLHIV has been robust, but less attention has been 
given to the clinical management of reversible CAD risk factors in HIV-infected persons. 
Over the last three decades, a high proportion of HIV-infected patients have been treated by 
providers with infectious diseases specialty training, and the favorable impact of expert HIV 
care on patient outcomes has been demonstrated previously (Landon et al., 2005). The 
efficacy of improved antiretroviral therapy has diminished the frequency of opportunistic 
infections in HIV-infected persons in the USA, and HIV-associated non-AIDS conditions 
(HANA) have emerged as major causes of morbidity and mortality in this population 
(Justice and Braithwaite, 2012; Mills, Barnighausen, & Negin, 2012; Rabkin, Kruk, & El-
Sadr, 2012) . Among the HANA conditions, CAD is the most prevalent in the general 
population, causing over 500,000 deaths a year in the USA (Gillespie et al., 2013). The 
clinical management of coronary artery risk in HIV clinics has not been rigorously studied, 
nor has such care been compared directly to that of uninfected persons. The present study 
compares CAD risk factor management among persons cared for in a large, university-based 
HIV specialty clinic to management of a matched cohort of demographically similar 
uninfected persons cared for in an academic Internal Medicine clinic.
Methods
Study setting
All HIV-infected persons in the study were treated at the Duke University Adult Infectious 
Diseases clinic between 1996 and 2010. The Duke ID clinic actively provides medical care 
to approximately 2000 HIV-infected persons. HIV primary care is provided by 10 full-time 
infectious diseases faculty with individual panels of 125–150 patients, 2 mid-level providers, 
and 6 infectious diseases panels with panels of 50–75 patients each. Uninfected persons in 
the control cohort were treated at the Duke Outpatient Clinic, the medical center’s largest 
clinic affiliated with the Internal Medicine training program. The clinic provides medical 
care to approximately 3500 active patients, in a typical resident supervision structure. Three 
faculty members also care for a full panel of patients at this site. The study was approved by 
the Institutional Review Board of the academic medical center.
Eligibility criteria
The study protocol was initially approved on 1 March 2010 and all data in the study were 
obtained from routine clinic visits prior to this date. All patients aged 40 or over (as of 1 
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March 2010) who attended at least three separate clinic visits over a span of at least 12 
months were eligible. Patients with a known history of cardiovascular disease 
(asymptomatic CAD, stable angina, or acute coronary syndrome), peripheral vascular 
disease, or stroke were excluded from the study. The exclusion diagnoses were identified by 
clinic ICD-9 billing data by query of the Duke Enterprise Data Unified Content Explorer 
and corroborated by chart review of provider-documented problem lists. HIV-infected 
persons who received ongoing non-HIV outpatient care from providers outside of the 
academic HIV specialty clinic were also excluded. Only patient encounters that occurred 
between 1 January 1996 and 1 March 2010.
Clinical data source/matching
Potential study patients were identified by querying the search engine of the electronic 
medical record of the institution. Patient demographic data, laboratory results, medication 
lists and medical histories were manually abstracted from individual patient encounters 
documented in the electronic medical record. Demographic data were abstracted from the 
medical center’s HIV clinical case registry, which includes information on over 5000 HIV-
infected persons followed since 1995. Data on adverse health behaviors, including smoking, 
ethanol abuse, and cocaine use, were obtained from a longitudinal review of individual 
clinic notes. HIV-infected persons were matched 1:1 with presumed uninfected persons by 
age, sex, race, and ethnicity. Age matching was conducted by grouping individuals into five-
year age blocks (each HIV-infected person was directly matched with a person within five 
years of their age). Race/ethnicity groups were categorized as “White”, “Black” or “Other”, 
and as “Hispanic” or “non-Hispanic”. Persons of mixed race were recorded as “other”. Data 
on health insurance status from the index clinical encounter were obtained from the 
institutional billing database.
Outcomes
The primary outcome measure was prescription of a drug from one of more of three 
categories of medications associated with CAD risk factor modification: aspirin, HMG-CoA 
reductase inhibitors (“statins”), or anti-hypertensives. The specific drug or dose and the 
source of the original prescription were not considered.
Predictor variables
After matching (most patients were able to be matched 1:1 by age, race/ethnicity, and sex), 
the explanatory variable of interest was HIV status. HIV-seropositivity was defined as 
having a documented history of HIV-infection prior to 1 March 2010. Predictor variables 
included diabetes, current or former cigarette smoking, cocaine use, and insurance status at 
index visit. The five most recent outpatient systolic and diastolic blood pressures, and the 
three most recent lipid profiles (total cholesterol, LDL-c, and HDL) from the study period 
were also collected. Ten-year CAD risk scores were calculated using abstracted data and the 
previously described Framingham Risk Equation (Wilson et al., 1998).
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The mean and standard deviations are reported for all continuous variables. Categorical 
variables are reported as frequencies and percentages. Multivariable analyses were done 
using logistic regression models for crude and adjusted ORs and associated 95% confidence 
intervals. The two cohorts were matched by age, race/ethnicity, and sex, and thus these 
variables were excluded from the logistic regression model. Variables included in the final 
regression model determined a priori include: HIV status, diabetes, former or current 
tobacco use, and insurance status at index visit (as categorical variables). For regression 
purposes, individual systolic and diastolic blood pressure, total cholesterol, LDL, and HDL 
values were all aggregated as mean values across a single observation (continuous 
variables). A backward reduction approach was used to eliminate non-associated variables 
from the final model with a significance level (α) of 0.20 (Steyerberg, Eijkemans, Van 
Houwelingen, Lee, & Habbema, 2000). Covariates known to be associated with the outcome 
variable were left in the final model regardless of associated p-values. Analyses were 
performed using SAS statistical software (Cary, North Carolina) version 9.3.
Results
A total of 1152 HIV-infected patients met the pre-specified inclusion criteria, of whom 262 
were excluded (receiving concurrent outpatient primary care from non-HIV providers), 
leaving a final HIV-infected cohort of 890 persons (Figure 1). Matching using the pre-
specified criteria was accomplished for 807 of these patients leaving a final analysis cohort 
of 890 HIV-infected persons and 807 controls. The mean ages (+/− standard deviation) for 
the infected and uninfected groups were 49.6 ± 7.0 years and 49.0 ± 6.5 years, respectively. 
A majority of the patients in the study cohorts were African-American (51% in the infected 
cohort, 55% in the uninfected cohort), and about three-quarters were male. The distribution 
of health insurance status was similar between the groups: HIV-infected (43% private 
insurance, 41% public insurance, and 16% uninsured); controls (40% private insurance, 43% 
public insurance, and 17% uninsured). Among HIV-infected persons, the median CD4 count 
was 501 cells/mm3 and 47% of the cohort maintained a viral load <50 copies/mL for six 
months or more. The mean systolic blood pressure (SBP) was lower in the HIV-infected 
group than in the uninfected group (128.4 ± 12.6 vs. 130.8 ± 14.2 mmHg, p < .001). The 
mean LDL-c (107.2 ± 34.5 vs. 111.2 ± 35.8 mg/dL, p = .03) and HDL (44.9 ± 19.2 vs. 47.9 
± 16.2, p < .001) were also lower in the infected group than in the uninfected group. There 
were similar numbers of current/former smokers in the two groups (48% vs. 46%) but fewer 
persons with a history of cocaine use than in the uninfected group (13 vs. 17%). The median 
10-year Framingham risk score for both groups was 3 (Table 1).
Despite similar CAD risk profiles, use of medications in all three CAD prevention 
categories was significantly less in the HIV-infected population. Aspirin was prescribed 
significantly less often in the HIV-infected group than in the uninfected group (11.6% vs. 
22.7%, p < .001). The same pattern was observed both for statin prescriptions (15.1% vs. 
23.6%, p < .001) and for anti-hypertensive drug prescriptions (35.7 vs. 52%, p < .001). In 
the univariate analysis, diabetes and increased mean SBP were associated with increased 
odds of aspirin and anti-hypertensive prescribing, as would be anticipated. Increased mean 
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LDL-c, decreased mean HDL, increased mean SBP, and a diagnosis of diabetes were 
associated with increased odds of statin prescribing. Current tobacco use and having private 
health insurance were associated with decreased odds of being prescribed a statin (Tables 2, 
3 and 4). For all three medications categories, being HIV-infected was associated with 
decreased likelihood of being prescribed the medication. After adjusting for potential 
confounding variables in the multivariable regression analysis (DM, mean SBP for ASA and 
anti-hypertensives, mean LDL, HDL, SBP, and diabetes for statins), HIV-infected persons 
were significantly less likely to be prescribed aspirin (adjusted OR 0.53 [95% CI, 0.40–
0.71]), statins (adjusted OR 0.70 [95% CI, 0.53–0.92]) and anti-hypertensives (adjusted OR 
0.63 [95% CI, 0.50–0.79]) than were persons in the control cohort (Table 5).
Discussion
Dramatic improvements in survival with contemporary antiretroviral treatment regimens 
have led to the emergence of non-AIDS conditions as major causes of death among HIV-
infected persons (Effros et al., 2008; Friis-Moller et al., 2010; Mocroft et al., 2010; Palella et 
al., 2006). The goal of this study was to determine if patients treated by specialist physicians 
with expertise in HIV care were managed comparably to persons in the control group treated 
by general internists in the prevention of one major HANA condition – CAD. As it relates to 
primary prevention of CAD, these data indicate that HIV-infected persons cared for in an 
HIV specialty clinic were significantly less likely to be prescribed aspirin, statins, and anti-
hypertensive agents, after adjusting for relevant CAD risk factors, than were similar control 
patients cared for in an academic Internal Medicine practice.
Concerns regarding the adequacy of primary CAD prevention in HIV-infected patients have 
been described previously. An analysis of the HIV Outpatient Study Cohort revealed that 
only about 60% of patients in the cohort met Joint National Commission on Prevention, 
Detection, Evaluation and Treatment of Hypertension (JNC–VII) guidelines for 
management of hypertension (Lichenstein et al., 2013). A recent study from the University 
of Alabama-Birmingham’s 1917 HIV clinic showed that only 17% of HIV-infected patients 
eligible for aspirin per US Preventative Service Task Force guidelines were receiving it 
(Burkholder et al., 2012). Although neither study included a comparator group, the relatively 
low frequency with which guidelines were met is concerning. Whether these observed low 
levels of adherence to treatment guidelines refiect patient care patterns in general or whether 
they may be related to provision of care by specialty clinicians rather than generalists has 
not been examined. Our study highlighting the differences in CAD care in two comparable 
populations suggests that the problem may be at least in part a reflection of the latter 
concern.
This concern is amplified by the fact that HIV-infected persons are at higher risk of CAD 
than the general population (Currier et al., 2003; Durand, Sheehy, Baril, Lelorier, & 
Tremblay, 2011; Klein, Hurley, Quesenberry, & Sidney, 2002; Obel et al., 2007; Triant, 
Lee, Hadigan, & Grinspoon, 2007). A recent analysis of the 82,000-person Veterans Aging 
Cohort Study showed that compared to uninfected persons, HIV-infected veterans were 
approximately 50% more likely to have a myocardial infarction during the study period after 
adjusting for traditional risk factors (Freiberg et al., 2013). In addition, there is accumulating 
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evidence that the pathophysiology of CAD may be different in persons with HIV-infection, 
driven more by immune activation and adverse metabolic conditions (dyslipidemia and 
hyperglycemia) than is otherwise the case (Deeks and Phillips, 2009; Hsue et al., 2009; 
Hsue, Deeks, & Hunt, 2012; Kaplan et al., 2011; Oliviero et al., 2009). In that regard, it has 
been suggested that statins may have the dual role of both improving lipids and diminishing 
immune activation essential to atheroma formation in HIV-infected persons (Calza et al., 
2013; Eckard, Jiang, Debanne, Funderburg, & McComsey, 2014). In a similar vein, aspirin 
may be important in decreasing markers of T cell and monocyte activation in HIV-infected 
persons, in addition to its well-known effects on platelet aggregation (O’Brien et al., 2013; 
Seshasai et al., 2012; Wolff, Miller, & Ko, 2009).
Because of the expertise required to successfully man-age chronic HIV-infection and its 
complications, many HIV providers may not be as knowledgeable about the finer points of 
general non-HIV related chronic disease care. Specifically, the differences in CAD 
prevention care observed in our study perhaps are related to the relative unfamiliarity of the 
providers with current recommendations for management of CAD risk. For example, a 
recent study by Fultz and colleagues found that ID physicians treating HIV-infected patients 
less frequently reported being comfortable treating hypertension, hyperlipidemia, or diabetes 
than did general internists who cared for HIV-infected persons [HTN: 73 vs. 98%, HL: 71 
vs. 98%, DM: 57 vs. 98%] (Fultz et al., 2005). While recent changes in guidelines for 
treating hyperlipidemia have made things simpler, programs aimed at updating knowledge 
of chronic disease management customized for the HIV provider are warranted (Stone et al., 
2013).
Our study has several limitations. First, this study was conducted in a single academic 
medical center located in the Southeastern USA and thus may not reflect care in other 
geographic areas with differing patient populations. Future studies will look to validate our 
identified predictors for medication prescription in a multi-center cohort. A concerted effort 
was made to identify a well-matched control population as a comparison group to the HIV-
infected patients cared for in the specialty clinic, but the difficulty of this task is illustrated 
in the imbalance in the size of the final analysis cohorts. To ensure that the major 
confounder of access-to-care was not a significant factor in our comparative analysis, the 
comparator cohort was selected from a socioeconomic status (SES) group similar to that of 
the HIV clinic population, using health insurance status as a surrogate marker. Although not 
a perfect surrogate for SES, the distribution of insurance status was strikingly similar in the 
two groups. As mentioned previously, this variable was adjusted for in the multivariable 
regression analysis. Details of the antiretroviral regimens being administered to HIV-
infected persons were not collected in this study. This may be significant for two reasons. 
First, the impact of pill burden on the provider’s propensity to prescribe additional 
medication was not taken into consideration, and, second, potential drug interactions 
between HIV protease inhibitors and many statins are well documented (Busti et al., 2008; 
Fichtenbaum et al., 2002; Hsyu, Schultz-Smith, Lillibridge, Lewis, & Kerr, 2001). Patients 
taking HIV protease inhibitors may thus be less likely to be prescribed a statin. Finally, 
given that this was a casecontrol study, standardizing the longitudinal period of follow up of 
clinical data was limited by the availability of individual data points. Although we set 
relatively stringent criteria on the ambulatory clinical data that we incorporated into the final 
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analysis, there may be some variability in the breadth of follow-up time that the clinical data 
on each individual patient represents.
This study of adherence to CAD prevention and management guidelines demonstrated that 
patients cared for in an HIV specialty clinic were less likely to be treated with aspirin, anti-
hypertensive medication, and lipidlowering drugs than were persons in the control group of 
similar CAD risk cared for in an academic internal medicine primary care clinic. Emerging 
evidence of HIV-infection as an additional CAD risk factor adds to the importance of good 
CAD preventive care for PLHIV. Our findings suggest that there is an important need to 
implement programs to equip all HIV providers with the knowledge base to navigate the 
increasingly complex demands of comprehensive HIV care, particularly in light of the rising 
importance of HANA conditions in the aging HIV population. Understanding and 
optimizing preventive care in PLHIV is essential in maintaining the substantial advances in 
prognosis for those with HIV-infection.
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Consort diagram of selection of study cohort from the duke university infectious diseases 
clinic.
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Table 1
Characteristics of HIV-infected persons and matched controls in study cohort.
HIV Infected










Age, years, Mean ± SD 49.6 ± 7.1 49.0 ± 6.5 49.3 ± 6.8
Male sex 688 (77) 614 (76) 1302 (77)
Race/ethnicity
 White/non-Hispanic 391 (44) 333 (41) 724 (43)
 Black 450 (51) 443 (55) 893 (52)
 White/Hispanic 19 (2) 13 (2) 32 (2)
 Other 30 (3) 18 (2) 48 (3)
Insurance
b
 Medicare/Medicaid 362 (41) 349 (43) 711 (42)
 Private 385 (43) 321 (40) 706 (42)
 None 140 (16) 135 (17) 275 (16)
Tobacco
b
 Ever 396 (48) 368 (46) 764 (47)
 Never 433 (52) 434 (54) 867 (53)
Current cocaine use
b 112 (13) 133 (17) 245 (15)
Diabetes mellitus
b 61 (7) 160 (20) 221 (13)
Systolic blood pressure, mmHg, Mean ± SD 128.5 ± 12.9 130.8 ± 14.2 129.6 ± 13.6
Total cholesterol, mg/dL, Mean ± SD 190.5 ± 56.5 189.1 ± 50.6 189.8 ± 53.9
LDL, mg/dL, Mean ± SD 107.2 ± 34.5 111.2 ± 35.8 109.0 ± 35.2
HDL, mg/dL, Mean ± SD 44.8 ± 19.2 47.9 ± 16.2 46.3 ± 17.9
CD4 count, Mean ± SD 531.4 ± 324.1 n/a n/a
CD4 Nadir 227.8 ± 211.1 n/a n/a
Viral suppression
 <400 copies/mL 570 (64) n/a n/a
 <50 copies/mL 423 (48) n/a n/a




3 (0–5) 3 (0–5) 3 (0–5)
10-year risk score for CAD
event ≥10%
c
34 (4) 26 (3) 60 (4)
Abbreviations: CAD, coronary artery disease; HDL, high density lipoprotein; HIV, human immunodeficiency virus; IQR, interquartile range; LDL, 




Missing data (counts): Cocaine, 15; Insurance, 5; Tobacco, 66.
c
Based on Framingham Risk Score for Coronary Heart Disease.
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Table 2






























































































































Note: Bold, meets statistical significance at p-value < 0.05.




Adjusting for all relevant clinical risk factors discussed in text.
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Table 3
































































































































Note: Bold, meets statistical significance at p-value < 0.05.




Adjusting for all relevant clinical risk factors discussed in text.
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Table 4
































































































































Note: Bold, meets statistical significance at p-value < 0.05.




Adjusting for all relevant clinical risk factors discussed in text.
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Table 5
Odds ratios for aspirin, statin, and anti-hypertensive prescription among HIV-Positive Persons (n = 890) 









b 0.44 (0.34–0.58) 0.53 (0.40–0.71) <0.0001
Statin




0.51 (0.42–0.62) 0.63 (0.50–0.79) <0.0001
a
Reference = uninfected persons.
b
Covariates in model for aspirin prescription include diabetes, mean systolic blood pressure, mean high density lipoprotein (HDL), and HIV-
infection.
c
Covariates in model for aspirin prescription include diabetes, private insurance, mean total cholesterol, mean LDL-c, mean HDL, and HIV-
infection.
d
Covariates in model for anti-hypertensive prescription include diabetes, mean systolic blood pressure, smoking, and HIV-infection.
AIDS Care. Author manuscript; available in PMC 2016 April 01.
